Latently human immunodeficiency virus (HIV)-infected cells are transcriptionally quiescent and invisible to clearance by the immune system. To demonstrate that the latency reversing agent vorinostat (VOR) induces a window of vulnerability in the latent HIV reservoir, defined as the triggering of viral antigen production sufficient in quantity and duration to allow for recognition and clearance of persisting infection, we developed a latency clearance assay (LCA). The LCA is a quantitative viral outgrowth assay (QVOA) that includes the addition of immune effectors capable of clearing cells expressing viral antigen. Here we show a reduction in the recovery of replication-competent virus from VOR exposed resting CD4 T cells following addition ...
Promising therapeutic approaches for eradicating HIV include transcriptional activation of provirus ...
Recent efforts to cure human immunodeficiency virus type-1 (HIV-1) infection have focused on develop...
The so-called shock and kill therapies aim to combine HIV-1 reactivation by latency-reversing agents...
Latently human immunodeficiency virus (HIV)-infected cells are transcriptionally quiescent and invis...
Despite antiretroviral therapy, proviral latency of human immunodeficiency virus type 1 (HIV-1) rema...
Approaches to deplete persistent HIV infection are needed. We investigated the combined impact of th...
Background. A single dose of the histone deacetylase inhibitor vorinostat (VOR) up-regulates HIV RNA...
BACKGROUND. The histone deacetylase (HDAC) inhibitor vorinostat (VOR) can increase HIV RNA expressio...
<div><p></p><p>Human immunodeficiency virus (HIV) persistence in latently infected resting memory CD...
Antiretroviral therapy regimens durably suppress HIV replication, but do not cure infection. This is...
UNLABELLED: Human immunodeficiency virus (HIV) persistence in latently infected resting memory CD4+ ...
HIV-1 eradication strategies aim to achieve viral remission in the absence of antiretroviral therapy...
Despite the extraordinary success of HIV-1 antiretroviral therapy in prolonging life, infected indiv...
HIV-1 eradication strategies aim to achieve viral remission in the absence of antiretroviral therapy...
The ‘shock and kill’ approach to cure human immunodeficiency virus (HIV) includes transcriptional in...
Promising therapeutic approaches for eradicating HIV include transcriptional activation of provirus ...
Recent efforts to cure human immunodeficiency virus type-1 (HIV-1) infection have focused on develop...
The so-called shock and kill therapies aim to combine HIV-1 reactivation by latency-reversing agents...
Latently human immunodeficiency virus (HIV)-infected cells are transcriptionally quiescent and invis...
Despite antiretroviral therapy, proviral latency of human immunodeficiency virus type 1 (HIV-1) rema...
Approaches to deplete persistent HIV infection are needed. We investigated the combined impact of th...
Background. A single dose of the histone deacetylase inhibitor vorinostat (VOR) up-regulates HIV RNA...
BACKGROUND. The histone deacetylase (HDAC) inhibitor vorinostat (VOR) can increase HIV RNA expressio...
<div><p></p><p>Human immunodeficiency virus (HIV) persistence in latently infected resting memory CD...
Antiretroviral therapy regimens durably suppress HIV replication, but do not cure infection. This is...
UNLABELLED: Human immunodeficiency virus (HIV) persistence in latently infected resting memory CD4+ ...
HIV-1 eradication strategies aim to achieve viral remission in the absence of antiretroviral therapy...
Despite the extraordinary success of HIV-1 antiretroviral therapy in prolonging life, infected indiv...
HIV-1 eradication strategies aim to achieve viral remission in the absence of antiretroviral therapy...
The ‘shock and kill’ approach to cure human immunodeficiency virus (HIV) includes transcriptional in...
Promising therapeutic approaches for eradicating HIV include transcriptional activation of provirus ...
Recent efforts to cure human immunodeficiency virus type-1 (HIV-1) infection have focused on develop...
The so-called shock and kill therapies aim to combine HIV-1 reactivation by latency-reversing agents...